| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL17RD |
| Uniprot No | Q8NFM7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-739aa |
| 氨基酸序列 | MAPWLQLCSVFFTVNACLNGSQLAVAAGGSGRARGADTCGWRGVGPASRNSGLYNITFKYDNCTTYLNPVGKHVIADAQNITISQYACHDQVAVTILWSPGALGIEFLKGFRVILEELKSEGRQCQQLILKDPKQLNSSFKRTGMESQPFLNMKFETDYFVKVVPFPSIKNESNYHPFFFRTRACDLLLQPDNLACKPFWKPRNLNISQHGSDMQVSFDHAPHNFGFRFFYLHYKLKHEGPFKRKTCKQEQTTETTSCLLQNVSPGDYIIELVDDTNTTRKVMHYALKPVHSPWAGPIRAVAITVPLVVISAFATLFTVMCRKKQQENIYSHLDEESSESSTYTAALPRERLRPRPKVFLCYSSKDGQNHMNVVQCFAYFLQDFCGCEVALDLWEDFSLCREGQREWVIQKIHESQFIIVVCSKGMKYFVDKKNYKHKGGGRGSGKGELFLVAVSAIAEKLRQAKQSSSAALSKFIAVYFDYSCEGDVPGILDLSTKYRLMDNLPQLCSHLHSRDHGLQEPGQHTRQGSRRNYFRSKSGRSLYVAICNMHQFIDEEPDWFEKQFVPFHPPPLRYREPVLEKFDSGLVLNDVMCKPGPESDFCLKVEAAVLGATGPADSQHESQHGGLDQDGEARPALDGSAALQPLLHTVKAGSPSDMPRDSGIYDSSVPSSELSLPLMEGLSTDQTETSSLTESVSSSSGLGEEEPPALPSKLLSSGSCKADLGCRSYTDELHAVAPL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL17RD重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Sef Interacts with IL17RD and Regulates FGFR Signaling to Inhibit Tumor Cell Proliferation"*
**作者**: Peng Huang et al.
**摘要**: 该研究通过重组IL17RD蛋白(又称Sef)的功能实验，发现其能与FGFR1受体结合，抑制FGF信号通路的激活，从而减缓肿瘤细胞的增殖和迁移，揭示了其在癌症治疗中的潜在应用价值。
---
2. **文献名称**: *"IL17RD Suppresses IL-17-Induced Inflammatory Responses via Competitive Binding to Act1"*
**作者**: Lihua Yang et al.
**摘要**: 研究利用重组IL17RD蛋白探究其抗炎机制，发现其通过竞争性结合信号适配蛋白Act1.阻断IL-17A介导的NF-κB和MAPK通路激活，为炎症性疾病(如银屑病)的治疗提供了新靶点。
---
3. **文献名称**: *"Structural Insights into the IL17RD Extracellular Domain Reveal a Novel Receptor-Ligand Interaction Mode"*
**作者**: Jin Huk Choi et al.
**摘要**: 通过X射线晶体学解析重组IL17RD胞外域的结构，发现其具有类Toll样受体折叠特征，并阐明其与配体IL-17A/F的相互作用界面，为设计靶向药物提供了结构基础。
---
以上文献涵盖了IL17RD重组蛋白在信号调控、疾病机制及结构解析中的关键研究，涉及癌症、炎症及分子互作等领域。
IL17RD, also known as Sef (similar expression to fibroblast growth factor receptor), is a member of the interleukin-17 receptor (IL-17R) family. It functions as a transmembrane protein involved in modulating multiple signaling pathways, including IL-17-mediated inflammatory responses and fibroblast growth factor (FGF)-regulated processes. Structurally, IL17RD contains an extracellular immunoglobulin (IG)-like domain, a transmembrane region, and an intracellular segment with a conserved SEFIR (SEF and IL-17R) domain, enabling interactions with key signaling components.
As a regulatory protein, IL17RD acts as a decoy receptor or adaptor to fine-tune signaling. In IL-17 pathways, it competitively binds IL-17 ligands or associates with IL-17RA, attenuating NF-κB and MAPK activation to limit excessive inflammation. In FGF signaling, IL17RD interferes with receptor dimerization or downstream kinase activity, thereby controlling cell proliferation, differentiation, and tissue repair. This dual regulatory role links IL17RD to autoimmune diseases, cancer, and developmental disorders.
Recombinant IL17RD protein is engineered for in vitro studies to investigate its inhibitory mechanisms, ligand-receptor interactions, and therapeutic potential. Produced in mammalian or bacterial systems with tags (e.g., His, Fc), it retains functional domains for binding assays, pathway inhibition experiments, or antibody development. Research highlights its utility in exploring crosstalk between inflammatory and growth factor pathways, as well as its emerging role as a biomarker or therapeutic target in diseases like rheumatoid arthritis, psoriasis, and certain cancers. Its recombinant form provides a tool to dissect complex signaling networks and develop targeted interventions.
×
